Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Clinical Trial
. 2014 Feb;32(1):87-93.
doi: 10.1007/s10637-013-9949-4. Epub 2013 Mar 24.

A First-In-Human Dose-Escalation Study of ME-143, a Second Generation NADH Oxidase Inhibitor, in Patients With Advanced Solid Tumors

Free PMC article
Clinical Trial

A First-In-Human Dose-Escalation Study of ME-143, a Second Generation NADH Oxidase Inhibitor, in Patients With Advanced Solid Tumors

Shubham Pant et al. Invest New Drugs. .
Free PMC article


Background: ME-143, a second-generation tumor-specific NADH oxidase inhibitor, is broadly active against human cancers in vitro and in vivo. This first-in-human dose-escalation study evaluated the dose-limiting toxicities (DLTs), pharmacokinetics, safety, tolerability, and preliminary anti-tumor activity of ME-143 in patients with advanced solid tumors.

Methods: Patients with advanced solid tumors were treated in a 3 + 3 escalation design. ME-143 was administered via intravenous infusion on days 1, 8, and 15 of the first 28-day cycle, and weekly thereafter; the final cohort received twice-weekly treatment. Samples for pharmacokinetic analysis were collected during cycle 1. Treatment continued until disease progression or unacceptable toxicity.

Results: Eighteen patients were treated: 2.5 mg/kg (n = 3); 5 mg/kg (n = 3); 10 mg/kg (n = 3); 20 mg/kg (n = 6); 20 mg/kg twice-weekly (n = 3). There were no DLTs observed. Nearly all treatment-related toxicities were grade 1/2, specifically (all grades) nausea (22 %) and fatigue (17 %). Two patients experienced infusion reactions at the 20 mg/kg dose level, one of which was grade 4. Stable disease was documented in three patients with colorectal cancer, cholangiocarcinoma, and anal cancer. Pharmacokinetic exposures were linear and dose-dependent, with a half-life of approximately 5 h.

Conclusions: ME-143 was well-tolerated when administered intravenously at the maximally administered/recommended phase 2 dose of 20 mg/kg once weekly to patients with advanced solid tumors. Though limited clinical activity was observed with monotherapy, inhibitors of tumor-specific NADH oxidase such as ME-143 may derive their greatest benefit in combination with cytotoxic chemotherapy.


Fig. 1
Fig. 1
ME-143 Dose versus Day 1 and Day 15 AUCs

Similar articles

See all similar articles

Cited by 4 articles


    1. Morre D, Chueh P, Yagiz K, et al. ECTO-NOX target for the anticancer isoflavone Phenoxodiol. Oncol Res. 2007;16:299–312. - PubMed
    1. Silasi D-A, Alvero AB, Rutherford TJ, et al. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother. 2009;10:1059–1067. doi: 10.1517/14656560902837980. - DOI - PubMed
    1. Kelly M, Mor G, Husband A, et al. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int J Gynecol Cancer. 2011;21:633–639. doi: 10.1097/IGC.0b013e3182126f05. - DOI - PubMed
    1. Herst P, Peterson T, Jerram P, et al. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007;74:1587–1595. doi: 10.1016/j.bcp.2007.08.019. - DOI - PubMed
    1. Wang X, McKernan R, Kim K, et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs. 2011;22:719–731. doi: 10.1097/CAD.0b013e328346f3b4. - DOI - PubMed

Publication types

MeSH terms